Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 2002-2010

Therapeutic Drug Monitoring

Volumn 34, Issue 3, 2012, Pages 349-355

  Bowskill, Sally V J ^a   Handley, Simon A ^a   Fisher, Danielle S ^a   Flanagan, Robert J ^a   Patel, Maxine X ^b  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adherence; Risperidone; Risperidone long acting injection; Schizophrenia; Total 9 hydroxyrisperidone

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOPAMINE 2 RECEPTOR; DRUG METABOLITE; LONG ACTING DRUG; PALIPERIDONE; RISPERIDONE;

ADOLESCENT; ADULT; CHILD; CIGARETTE SMOKING; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG METABOLISM; DRUG MONITORING; FEMALE; HEALTH SERVICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DATABASES, FACTUAL; DRUG MONITORING; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PYRIMIDINES; RISPERIDONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862097847     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182577c43     Document Type: Review

References (28)

1. Hiemke C, Dragicevic A, Gründer G, et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit. 2004;26:156-160. (Pubitemid 38501210)
2. Couchman L, Morgan PE, Spencer EP, et al. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit. 2010;32:438-447.
3. Patel MX, Bowskill S, Couchman L, et al. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009. J Clin Psychopharmacol. 2011;31:411-417.
4. Schwenger E, Dumontet J, Ensom MH. Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia? Clin Pharmacokinet. 2011;50:415-428.
5. Heimke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.
6. De Meulder MD, Remmerie BMM, de Vries R, et al. Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine. J Chromatogr B. 2008;870:8-16.
7. Van Beijsterveldt LE, Geerts RJ, Leysen JE, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat. Psychopharmacology (Berl). 1994;114:53-62. (Pubitemid 24150520)
8. Olesen OV, Licht RW, Thomsen E, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20:380-384. (Pubitemid 28359985)
9. Eerdekens M, Van Hove I, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70:91-100. (Pubitemid 38916632)
10. Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database Syst Rev. 2009;7:CD007474.
11. Remington G, Mamo D, Labelle A, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatr. 2006;163:396-401. (Pubitemid 44469380)
12. Mauri MC, Laini V, Boscati L, et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatr. 2001;16:7-63.
13. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines. 10 ed. London: Informa Healthcare, 2009.
14. BMJ Group and Pharmaceutical Press. British National Formulary. 62 ed. London: BMJ Group and RPS Publishing, 2011.
15. UKPPG (United Kingdom Psychiatric Pharmacy Group). Guidelines for use of risperidone long-acting injection. 2006. Available at: http://www. ukppg.org.uk/02-09-risperidone-consta-1.html. Accessed September 28, 2011.
16. Volonteri LS, Cerveri G, De Gaspari IF, et al. Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients. Psychopharmacology (Berl). 2010;210:489-497.
17. Flanagan RJ, Harvey EJ, Spencer EP. HPLC of basic drugs on microparticulate strong cation-exchange materials. Forensic Sci Int. 2001;121: 97-102. (Pubitemid 32758818)
18. FDA/CDER (Food and Drug Administration/Center for Drug Evaluation and Research). Guidance for industry. Bioanalytical method validation. 2001. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM070107.pdf. Accessed July 18, 2011.
19. Clinical and Laboratory Standards Institute. Evaluation of precision performance of quantitative measurement methods: approved guideline. Edition
20. Document EP05-A 2, 2004. Available at: http://webstore.ansi.org/ ansidocstore/product.asp?sku=EP05%2DA2. Accessed July 18, 2011.
21. Reis M, Aberg-Wistedt A, Agren H, et al. Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. J Affect Disorders. 2004;82:443-446. (Pubitemid 39536177)
22. Yasui-Furukori N, Saito M, Nakagami T, et al. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuropsychopharmacol Biol Psychiatr. 2010; 34:537-540.
23. de Leon J, Susce MT, Pan R-M, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007;40: 93-102. (Pubitemid 46910379)
24. Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit. 2001;23:223-227. (Pubitemid 32476548)
25. Aravagiri M, Marder SR, Nuechterlein KH, et al. Intra-and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003;25:657-664. (Pubitemid 37499299)
26. Jung SM, Kim K-A, Cho H-K, et al. Cytochrome P450 3A inhibitor itraconzole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005;78: 520-528. (Pubitemid 41698906)
27. Saito M, Yasui-Furukori N, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol. 2005;25:527-532. (Pubitemid 41669043)
28. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51:80-88.